P/E ratio for BioLineRx (BLRX)
P/E ratio as of June 2024 (TTM): -0.9109
According to BioLineRx's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.910889. At the end of 2022 the company had a P/E ratio of -1.31.
P/E ratio history for BioLineRx from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.31 | -60.27% |
| 2021 | -3.30 | 132.94% |
| 2020 | -1.42 | 57.07% |
| 2019 | -0.9020 | -62.12% |
| 2018 | -2.38 | -41.02% |
| 2017 | -4.04 | 22.87% |
| 2016 | -3.29 | -28.68% |
| 2015 | -4.61 | -6.2% |
| 2014 | -4.91 | 33.8% |
| 2013 | -3.67 | 66.86% |
| 2012 | -2.20 | -25.24% |
| 2011 | -2.94 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.